Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Buy” by Brokerages

Zoetis Inc. (NYSE:ZTSGet Rating) has earned an average rating of “Buy” from the eight brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $224.00.

A number of equities analysts recently commented on ZTS shares. Stifel Nicolaus dropped their price target on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, June 24th. The Goldman Sachs Group reduced their price objective on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a report on Thursday, July 21st. StockNews.com raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 9th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Friday, August 5th. Finally, Piper Sandler initiated coverage on Zoetis in a report on Monday, July 11th. They set an “overweight” rating and a $205.00 price objective for the company.

Insider Buying and Selling

In other Zoetis news, CEO Kristin C. Peck sold 311 shares of Zoetis stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the transaction, the chief executive officer now directly owns 39,743 shares of the company’s stock, valued at approximately $7,153,740. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Roxanne Lagano sold 4,334 shares of the company’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $175.00, for a total value of $758,450.00. Following the completion of the sale, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,145,225. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Kristin C. Peck sold 311 shares of Zoetis stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the transaction, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,501 shares of company stock valued at $2,949,073. 0.12% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zoetis

Several institutional investors have recently made changes to their positions in the stock. American National Bank grew its position in shares of Zoetis by 469.2% in the second quarter. American National Bank now owns 148 shares of the company’s stock valued at $25,000 after purchasing an additional 122 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares during the period. Worth Asset Management LLC acquired a new position in Zoetis during the first quarter worth approximately $26,000. Financial Management Professionals Inc. raised its position in shares of Zoetis by 117.4% in the 1st quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock worth $28,000 after buying an additional 81 shares during the period. Finally, Hanson & Doremus Investment Management boosted its holdings in Zoetis by 713.6% in the first quarter. Hanson & Doremus Investment Management now owns 179 shares of the company’s stock valued at $34,000 after acquiring an additional 157 shares during the last quarter. 91.05% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 1.2 %

Shares of NYSE ZTS opened at $157.30 on Friday. The stock has a market capitalization of $73.64 billion, a P/E ratio of 35.67, a PEG ratio of 2.79 and a beta of 0.77. Zoetis has a 1-year low of $154.18 and a 1-year high of $249.27. The business’s 50 day moving average is $169.59 and its two-hundred day moving average is $174.93. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.18 and a quick ratio of 1.46.

Zoetis (NYSE:ZTSGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.22 by ($0.02). Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the prior year, the firm posted $1.19 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, research analysts expect that Zoetis will post 5.01 EPS for the current year.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.